UNSPSC 51181626: Liothyronine hydrochloride

This classification denotes a generic primary tumor tnm finding with the molecular formula C15H12I3NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T66DHO0SET, chemically known as alanine, 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-, hydrochloride, l-, but more generally known as liothyronine hydrochloride, which bears US NIH Compound Identifier 71283. European Medicines Agency schedules liothyronine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08527MIG.

Most nations, for tariff purposes, schedule liothyronine hydrochloride under HS 29374000. SMILES: C1CC(C(CC1OC2C(CC(CC2I)C[C@@H](C(=O)O)N)I)I)O.CL.

UNSPSC 51181626 Liothyronine hydrochloride is a Commodity code covering a thyroid hormone replacement medication supplied to state and local government healthcare facilities through cooperative purchasing arrangements. State and local governments procure this pharmaceutical as part of broader multi-source generic drug programs administered through multistate cooperative purchasing alliances that consolidate demand across participating jurisdictions' Medicaid programs, correctional facilities, public health departments, and other government healthcare operations. The purchasing pattern reflects a managed pharmaceutical supply chain where state and local entities do not buy directly from manufacturers but instead negotiate pricing through cooperative agreements that route products through authorized wholesalers, allowing participating jurisdictions to access standardized pricing and reduce administrative overhead.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. The solicitation requires manufacturers to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded vendors effective July 1, 2026. Evaluation emphasizes price competitiveness (75 percent weight), compliance with administrative requirements including EDI capability, cGMP and Drug Supply Chain Security Act certification, and maintenance of contractual relationships with at least two of the three authorized wholesalers. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000; contract terms are two years for new responders with optional extensions or alignment with existing agreement expiration dates through June 30, 2028 for incumbents.